{"groups":[{"description":"Weeks 1-24: Oxaliplatin was administered as an 85 mg/m\\^2 intravenous infusion over 2 hours concomitantly with leucovorin as a 200 mg/m\\^2 infusion over 2 hours, followed by 5-fluorouracil (5-FU), given as a 400 mg/m\\^2 bolus injection, and then as a 600 mg/m\\^2 continuous infusion over 22 hours. Leucovorin 200 mg/m\\^2 (alone), followed by 5-FU 400 mg/m\\^2 bolus injection, and 5-FU 600 mg/m\\^2 continuous infusion were repeated on day 2. Cycle length was 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).\n\nWeeks 25-48: Observation only.","id":"FG000","title":"FOLFOX4"},{"description":"Weeks 1-24: Bevacizumab 5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin, administered as an 85 mg/m\\^2 intravenous infusion over 2 hours (on day 1 only) concomitantly with leucovorin, as a 200 mg/m\\^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m\\^2 bolus injection, and then as a 600 mg/m\\^2 continuous infusion over 22 hours. Leucovorin 200 mg/m\\^2 (alone), followed by 5-FU 400 mg/m\\^2 bolus injection, and 5-FU 600 mg/m\\^2 continuous infusion are repeated on day 2. Cycle length is 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).\n\nWeeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks).","id":"FG001","title":"FOLFOX4 + Bv"},{"description":"Weeks 1-24: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin administered as a 130 mg/m\\^2 intravenous infusion over 2 hours (day 1 every 3 weeks) in combination with capecitabine, which was administered orally at a dose of 1000 mg/m\\^2 twice daily (equivalent to a total daily dose of 2000 mg/m\\^2), with first dose the evening of day 1 and last dose the morning of day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment), for a total of 8 cycles (24 weeks).\n\nWeeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks).","id":"FG002","title":"XELOX+Bv"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"1151"},{"groupId":"FG001","numSubjects":"1155"},{"groupId":"FG002","numSubjects":"1145"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"1126"},{"comment":"Includes two patients from FOLFOX4 who received Bv and were assigned to FOLFOX4+Bv safety analysis","groupId":"FG001","numSubjects":"1145"},{"groupId":"FG002","numSubjects":"1135"}],"type":"Received Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"955"},{"groupId":"FG001","numSubjects":"960"},{"groupId":"FG002","numSubjects":"952"}],"type":"Stage III Disease Population"},{"achievements":[{"comment":"Represents patients alive in follow-up at the time of final data cut-off (30 June 2012)","groupId":"FG000","numSubjects":"854"},{"comment":"Represents patients alive in follow-up at the time of final data cut-off (30 June 2012)","groupId":"FG001","numSubjects":"810"},{"comment":"Represents patients alive in follow-up at the time of final data cut-off (30 June 2012)","groupId":"FG002","numSubjects":"846"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"297"},{"groupId":"FG001","numSubjects":"345"},{"groupId":"FG002","numSubjects":"299"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Randomization was stratified according to geographic region and disease stage (high-risk stage II or stage III N1 or stage III N2). The primary analysis population consisted of patients with Stage III disease."}